Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03934840 · ClinicalTrials.gov registry record · Phase 2

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

A Phase 2 study of Prostate Cancer, sponsored by Masonic Cancer Center, University of Minnesota.

Active
Registry status
Phase 2
Development phase
22
Enrollment target
8
Study locations

NCT03934840 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 22 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03934840, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
22 participants
Enrollment target
8
Study locations

Study Summary

This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2. Patients will be treated with the combination of ADT and carboplatin and cabazitaxel for 6 cycles. After 6 cycles of chemotherapy, they will start abiraterone with ADT. The primary objective is to determine the percent of subjects that have no PSA or radiographic progression at 1 year. Secondary objectives will include determining the progression-free survival, time to PSA nadir and time to PSA progression of carboplatin and cabazitaxel in combination with ADT.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Prednisone
  • DRUG Abiraterone
  • DRUG Cabazitaxel

Study Locations (8)

Illinois

  • Northwestern University - Chicago
  • University of Chicago - Chicago

Arizona

  • Mayo Clinic Arizona - Phoenix

Louisiana

  • Tulane University - New Orleans

Minnesota

  • Masonic Cancer Center at University of Minnesota - Minneapolis

Nevada

  • Comprehensive Cancer Centers of Nevada - Las Vegas

Pennsylvania

  • Thomas Jeferson University - Philadelphia

Rhode Island

  • Lifespan Cancer Institute - Providence

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-10-10
Est. Completion 2025-05
Phase Phase 2

Sponsor

Masonic Cancer Center, University of Minnesota

249 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03934840

The ClinicalTrials.gov registry entry for NCT03934840 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT03934840 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Illinois, Arizona, Louisiana.

Frequently Asked Questions

What is clinical trial NCT03934840 about?

NCT03934840 is a clinical study titled "CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone". This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2....

What is the current status of trial NCT03934840?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2019-10-10. Estimated completion is 2025-05.

What conditions does trial NCT03934840 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03934840?

The interventions under investigation include: Carboplatin (DRUG), Prednisone (DRUG), Abiraterone (DRUG), Cabazitaxel (DRUG).

Who is sponsoring clinical trial NCT03934840?

This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03934840 being conducted?

This trial has 8 study locations across Arizona, Illinois, Louisiana, Minnesota, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.